Search Results
Jun 15, 2026, 01:26 ET Menarini Group、European Hematology Association (EHA)の2026年総会にて、骨髄線維症を対象としたセリネキソールとルキソリチニブの併用療法に関する第3相SENTRY試験のデータを発表
*第36週までに脾臓の評価を完了した患者、または第36週以前に試験を中止した患者を対象に分析を行いました。「脾臓の縮小を達成することが、骨髄線維症治療の重要な目標です。「重要なのは、SENTRY試験で認められた脾臓の縮小が迅速かつ著明で持続的であり、この併用療法を受けた患者において全生存期間の延長が期待できるという点です」と、Guy's and St. Thomas' NHS Foundation Trustの骨髄増殖性腫瘍学教授 兼副医療責任者であるClaire Harrison博士は述べています。「これらの結果が、より良い治療法の選択肢を切実に必要としている患者にとって、新たな治療の進展につながる可能性があることを、私たちは心強く感じています。」その他のハイライトは以下の通りです。
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:17 ET 메나리니 그룹, 2026 유럽혈액학회(EHA) 학술대회에서 골수섬유증 대상 셀리넥서 및 룩소리티닙 병용요법의 제3상 SENTRY 시험 데이터 발표
23.0%(n=23)*36주 시점 이전에 비장 평가를 완료했거나 시험을 중단한 환자를 대상으로 분석 수행가이즈 앤드 세인트 토마스 NHS 재단 신탁(Guy's and St. Thomas' NHS Foundation Trust)의 골수증식성 종양 교수 겸 부최고의료책임자인 클레어 해리슨(Claire Harrison) 박사는 "비장 감소 달성은 골수섬유증 치료의 핵심 목표다. 특히 SENTRY에서 나타난 비장 감소 결과는 신속하고 심도
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:13 ET Menarini Group reporta datos del ensayo SENTRY de fase 3 de Selinexor Plus Ruxolitinib en mielofibrosis en el Congreso de la Asociación Europea de Hematología (EHA) 2026
recibieron la combinación ", dijo la Dra. Claire Harrison, profesora de neoplasias mieloproliferativas y directora médica adjunta de Guy's y St. Thomas 'NHS Foundation Trust. "Nos alienta que estos resultados representen un nuevo avance terapéutico potencial para nuestros pacientes que necesitan urgentemente
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:10 ET Grupo Menarini relata dados do Ensaio SENTRY de Fase 3 de Selinexor Plus Ruxolitinibe em mielofibrose no Congresso da Associação Europeia de Hematologia (EHA) 2026
que receberam a combinação ", disse a Dra. Claire Harrison, professora de neoplasias mieloproliferativas e vice-diretora médica da Guy's e St. Thomas 'NHS Foundation Trust. "Estamos animados com o fato de que esses resultados representam um potencial novo avanço terapêutico para nossos pacientes que precisam
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:06 ET Die Menarini Group präsentiert auf dem Kongress der European Hematology Association (EHA) 2026 Daten aus der Phase-3-Studie SENTRY zur Kombination von Selinexor und Ruxolitinib bei Myelofibrose
erhielten", sagte Dr. Claire Harrison, Professorin für myeloproliferative Neoplasien und stellvertretende medizinische Direktorin am Guy's and St. Thomas' NHS Foundation Trust. „Wir sind zuversichtlich, dass diese Ergebnisse einen potenziellen neuen therapeutischen Fortschritt für unsere Patienten darstellen,
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 07:26 ET Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
receiving the combination," said Dr. Claire Harrison, Professor of Myeloproliferative Neoplasms and Deputy Chief Medical Officer at Guy's and St. Thomas' NHS Foundation Trust. "We are encouraged that these results represent a potential new therapeutic advance for our patients who are in dire need of better
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 12, 2026, 12:00 ET Fleming Initiative and Cepheid Launch Landmark Study of Rapid Testing for Drug-Resistant Infections
support effective use of NHS resources and service delivery, protect patients and help inform national screening policy. The study will be at two of the hospitals run by Imperial College Healthcare NHS Trust and Guy's and St Thomas' NHS Foundation Trust, two of the largest NHS Trusts in England.The
More news about: Cepheid
Jun 12, 2026, 07:53 ET Infection-control readiness cannot wait for crisis, warns Hydrachem after Ebola response supply work
disinfection and sterilisation. Operating in over 60 countries, the company partners with NGOs, governments and leading healthcare institutions, including the NHS, to combat waterborne diseases, maintain hygienic environments and produce over 10 billion litres of safe drinking water each year.The company
More news about: Hydrachem
Jun 12, 2026, 05:55 ET UK's leading longevity clinic Get A Drip appoints new Chief Medical Officer Dr Luke Pratsides
His clinical outlook is rooted in preventative medicine and shaped by years of lived healthcare experience in both the private sector and frontline NHS practice. Dr Pratsides formerly led the medical team at Numan where he built the company's GLP-1 and testosterone hormone therapy prescribing
More news about: Get A Drip
Jun 11, 2026, 19:05 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines - GRAL
action]On February 19, 2026, Grail announced that "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. Grail attributed this shortcoming, in part, to "probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately." On
More news about: Pomerantz LLP
Jun 11, 2026, 12:39 ET Amedea Pharma, Inc. Announces Return of the Fifth Annual Medical Innovation Olympics at Rockefeller Center on June 12, 2026
unforgettable competition that replicates the Olympic spirit is to advance access, quality, and continuity of care. Past keynote speakers have included NHS UK consultant and champion athlete Chris Cook, Type 1 Diabetes patient advocate Gary Hall Jr., and longest-running world record holder Bob Beamon. The
More news about: Amedea Pharma, Inc.
Jun 11, 2026, 12:00 ET Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
reduction in Stage III–IV cancers in Grail's NHS-Galleri trial, creating the false impression that they possessed reliable information supporting such outcome while concealing adverse facts that diminished that possibility;Defendants' optimism regarding the NHS-Galleri study's prospects was overstated
More news about: Bronstein, Gewirtz & Grossman, LLC
Jun 11, 2026, 09:35 ET SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL
Wall Street's Reassessment of Grail: How Analyst Expectations Built on Positive NHS-Galleri Representations Collapsed Alongside GRAL's $51.32 Per-Share DeclineNEW YORK, June 11, 2026 /PRNewswire/ -- SueWallSt
More news about: SueWallSt.com
Jun 11, 2026, 06:30 ET GRAL INVESTOR ALERT: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
significant reduction in Stage III-IV cancers in Grail's NHS-Galleri trial, while also concealing material adverse facts which reduced the possibility of such an outcome; (ii) in truth, Grail's optimism in achieving the primary endpoint of its NHS-Galleri study fell short of reality; and (iii) the confidence
More news about: Robbins Geller Rudman & Dowd LLP
Jun 10, 2026, 09:00 ET Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL
after Grail disclosed the NHS-Galleri trial failed to achieve its primary endpoint. The lead plaintiff deadline is August 4, 2026.What They Allegedly KnewThe securities action contends that Grail's leadership possessed internal data from the NHS-Galleri prevalent screening
More news about: Levi & Korsinsky, LLP
Jun 09, 2026, 09:48 ET Axiom GRC accelerates North American expansion via acquisition of Canadian Assurance firm MHM
retention levels.Axiom clients include large businesses like Walmart, Sony, L'Oreal, Bentley, and Shell Energy, public sector bodies including NHS England, and thousands of SMEs across all sectors.About Axiom GRCAxiom GRC is a leading international platform offering comprehensive
More news about: Axiom GRC
Jun 09, 2026, 09:00 ET The Gross Law Firm Reminds GRAIL, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: The Gross Law Firm
Jun 08, 2026, 23:05 ET GRAL Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against Grail, Inc.
call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations that Grail, Inc. (GRAL) Misled Investors Concerning NHS-Galleri's Potential to Achieve statistically significant reduction in Stage III-IV cancersAccording to the complaint, during the class period, defendants
More news about: Robbins LLP
Jun 08, 2026, 18:52 ET GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: THE ROSEN LAW FIRM, P. A.
Jun 08, 2026, 08:00 ET NHS England accelerates AI adoption with Microsoft 365 Copilot to improve service delivery, reduce costs and create more time for care
access to the AI-powered assistant, NHS workers will be able to streamline administrative processes, improving capacity across NHS England Trusts, reducing costs and providing more time for patient care.Copilot helps users create, analyze and get work done faster. NHS England anticipates that Copilot
More news about: Microsoft Corp.
Jun 04, 2026, 09:17 ET Optellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and Growing
NHS and Intuitive Surgical to support end-to-end AI & robot lung cancer pathways in the UK. It is also reflected in established and new customer
More news about: Optellum
Jun 03, 2026, 08:00 ET HBSUK and Hexaware partner to enhance clinician onboarding efficiency
time. Since 2012, HBSUK has worked closely with the NHS and private providers to increase clinical capacity and improve patient experience, connecting digital and in-person pathways. By bringing together technology, data, and people, HBSUK empowers the NHS and private healthcare providers to deliver more
More news about: Hexaware Technologies Ltd
Jun 03, 2026, 06:26 ET HBSUK and Hexaware partner to enhance clinician onboarding efficiency
time. Since 2012, HBSUK has worked closely with the NHS and private providers to increase clinical capacity and improve patient experience, connecting digital and in-person pathways. By bringing together technology, data, and people, HBSUK empowers the NHS and private healthcare providers to deliver more
More news about: Hexaware Technologies Ltd
Jun 02, 2026, 10:02 ET Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
potential for disease modification with lower levels of VAF," said Dr. Claire Harrison, Professor of Myeloproliferative Neoplasms at Guy's and St. Thomas' NHS Foundation Trust in the United Kingdom. "JAK inhibitors have transformed the treatment landscape over the past 15 years, but there remains a significant
More news about: Karyopharm Therapeutics Inc.
Jun 01, 2026, 11:05 ET World Environment Day: Known water crisis still leaving billions at risk, Hydrachem warns
disinfection and sterilisation. Operating in over 60 countries, the company partners with NGOs, governments and leading healthcare institutions, including the NHS, to combat waterborne diseases, maintain hygienic environments and produce over 10 billion litres of safe drinking water each year.The company
More news about: Hydrachem